About this episode

The episode discusses the complexities of treatment decisions in breast cancer care following new data on ESR1 mutations.

In the wake of recent key data about ESR1-mutated metastatic breast cancer, treatment decisions have become more complicated. “In current clinical practice, this is not a straightforward decision,”Marla Lipsyc-Sharf, MD, explains to Robert A. Figlin, MD.

Explore listener stats, chart rankings, contacts and more on the Oncology News Central Peer-Spectives podcast page.